Anita Mamtani1, Varadan Sevilimedu2, Alain Vincent3, Monica Morrow3. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mamtana1@mskcc.org. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND: Despite advances in neoadjuvant systemic therapy (NST), some patients with aggressive T4 breast cancers do not respond. The efficacy of 'heroic' mastectomy in maintaining local control is unclear. METHODS: In consecutive patients with primary or recurrent T4 cancers with < 50% shrinkage on NST who underwent mastectomy from 2007 to 2017, clinicopathologic characteristics and locoregional recurrence (LRR) were examined. RESULTS: Among 104 patients, 59 (57%) had primary T4M0, 12 (12%) had locally recurrent T4M0, and 33 (32%) had T4M1 disease. Median age was 58.5 years and the majority had high-grade (74%) ductal cancers (85%); 45 (44%) were estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), 26 (25%) were HER2 positive (HER2+), and 31 (30%) were triple negative (TN). Postoperative complications developed in 41 (39%) patients. At a median follow-up of 37 months, 42 (40%) patients developed LRR. TN (hazard ratio [HR] 7.5) and HER2+ (HR 2.67) subtypes, lymphovascular invasion (LVI; HR 3.80), and positive margins (HR 4.09) were predictive of LRR. The 3-year LRR rate was highest and overall survival (OS) was lowest among patients with TN cancers, at 66% (95% confidence interval [CI] 48-83%) and 30% (95% CI 14-47%), respectively. CONCLUSIONS: After heroic mastectomy, postoperative complications were frequent and LRR occurred in 40% of patients despite a median OS of 3.8 years. Among TN patients, the 3-year LRR rate of 66% and 3-year OS of 30% suggest limited surgery benefit. Careful patient selection is prudent when considering heroic mastectomy.
BACKGROUND: Despite advances in neoadjuvant systemic therapy (NST), some patients with aggressive T4 breast cancers do not respond. The efficacy of 'heroic' mastectomy in maintaining local control is unclear. METHODS: In consecutive patients with primary or recurrent T4 cancers with < 50% shrinkage on NST who underwent mastectomy from 2007 to 2017, clinicopathologic characteristics and locoregional recurrence (LRR) were examined. RESULTS: Among 104 patients, 59 (57%) had primary T4M0, 12 (12%) had locally recurrent T4M0, and 33 (32%) had T4M1 disease. Median age was 58.5 years and the majority had high-grade (74%) ductal cancers (85%); 45 (44%) were estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), 26 (25%) were HER2 positive (HER2+), and 31 (30%) were triple negative (TN). Postoperative complications developed in 41 (39%) patients. At a median follow-up of 37 months, 42 (40%) patients developed LRR. TN (hazard ratio [HR] 7.5) and HER2+ (HR 2.67) subtypes, lymphovascular invasion (LVI; HR 3.80), and positive margins (HR 4.09) were predictive of LRR. The 3-year LRR rate was highest and overall survival (OS) was lowest among patients with TN cancers, at 66% (95% confidence interval [CI] 48-83%) and 30% (95% CI 14-47%), respectively. CONCLUSIONS: After heroic mastectomy, postoperative complications were frequent and LRR occurred in 40% of patients despite a median OS of 3.8 years. Among TN patients, the 3-year LRR rate of 66% and 3-year OS of 30% suggest limited surgery benefit. Careful patient selection is prudent when considering heroic mastectomy.
Authors: Aoife J Lowery; Malcolm R Kell; Ronan W Glynn; Michael J Kerin; Karl J Sweeney Journal: Breast Cancer Res Treat Date: 2011-12-07 Impact factor: 4.872
Authors: Eugene Huang; Marsha D McNeese; Eric A Strom; George H Perkins; Angela Katz; Gabriel N Hortobagyi; Vicente Valero; Henry M Kuerer; S Eva Singletary; Kelly K Hunt; Aman U Buzdar; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2002-08-01 Impact factor: 7.038
Authors: Antonio Di Meglio; Rachel A Freedman; Nancy U Lin; William T Barry; Otto Metzger-Filho; Nancy L Keating; Tari A King; Mario Roberto Sertoli; Francesco Boccardo; Eric P Winer; Ines Vaz-Luis Journal: Breast Cancer Res Treat Date: 2016-06-06 Impact factor: 4.872
Authors: T A Buchholz; B S Hill; S L Tucker; D K Frye; H M Kuerer; A U Buzdar; M D McNeese; S E Singletary; N T Ueno; L Pusztai; V Valero; G N Hortobagyi Journal: Cancer J Date: 2001 Sep-Oct Impact factor: 3.360
Authors: G N Hortobagyi; F C Ames; A U Buzdar; S W Kau; M D McNeese; D Paulus; V Hug; F A Holmes; M M Romsdahl; G Fraschini Journal: Cancer Date: 1988-12-15 Impact factor: 6.860
Authors: Hannah W Hazard; Seema R Gorla; Denise Scholtens; Krystyna Kiel; William J Gradishar; Seema A Khan Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: M Perloff; G J Lesnick; A Korzun; F Chu; J F Holland; M P Thirlwell; R R Ellison; R W Carey; L Leone; V Weinberg Journal: J Clin Oncol Date: 1988-02 Impact factor: 44.544
Authors: Paul L Nguyen; Alphonse G Taghian; Matthew S Katz; Andrzej Niemierko; Rita F Abi Raad; Whitney L Boon; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Marissa C van Maaren; Linda de Munck; Luc J A Strobbe; Gabe S Sonke; Pieter J Westenend; Marjolein L Smidt; Philip M P Poortmans; Sabine Siesling Journal: Int J Cancer Date: 2018-11-28 Impact factor: 7.396